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Mycosis fungoides with CD20
expression: report of two cases
and review of the literature
CD20 expression is exceedingly rare in T-cell lymphomas. Most
published cases have been diagnosed as peripheral T-cell lymphomas,
not otherwise specified. Only 18 cases of CD20-positive mycosis
fungoides (MF) have been previously reported. Here, we describe two
cases of CD20-positive MF. Patient 1 was an 84-year-old woman who
presented with a 5-year history of multiple pruritic erythematous
papules coalescing into thin plaques over 80% of her body surface area.
She expired after developing tumors and large cell transformation.
Patient 2 was a 67-year-old woman with a long-standing history of
tumor stage MF with large cell transformation. She developed a nodular
plaque while receiving topical and systemic therapy. In both cases, the
neoplastic T-cells demonstrated a CD4-positive immunophenotype
with loss of pan-T-cell markers and a monoclonal T-cell receptor
gamma gene rearrangement. CD20 was expressed by a significant
population of the neoplastic T-cells, but these T-cells lacked expression
of other B-cell markers, including CD79a, CD19 and PAX5. This
report adds to and summarizes the small body of literature describing
CD20-positive MF, and discusses diagnostic and clinical implications.
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CD20 is a 33- to 37-kDa transmembrane phos-
phoprotein expressed on B-cells that is thought to
regulate cellular calcium transport and thus cell
activation.1,2 It is expressed during B-cell develop-
ment, and expression is lost during differentiation
to plasma cells.2 CD20 is a well-characterized
marker of B-cell lymphomas and leukemias.2
However, rare cases of CD20-positive, mature T-cell
lymphomas have been described.3–9 The majority
of reported cases are extracutaneous and do not
meet the criteria for defined subtypes of T-cell
lymphoma. They have therefore been classified as
peripheral T-cell lymphoma, not otherwise specified
(PTCL, NOS), formerly termed peripheral T-cell
lymphoma-unspecified (PTCL-U).6,10,11 To our
knowledge, only 18 cases of CD20-positive T-cell
lymphomas have been designated as mycosis fun-
goides (MF).3,6,7,12–15 Here, we report two additional
cases of CD20-positive MF, review the literature
and discuss diagnostic and clinical implications.
Patient 1
An 84-year-old woman with a remote history of
breast cancer presented with pruritic, erythematous,
scaly papules and plaques that progressed over
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A B
Fig. 1. A clinical photograph of case 1 at the time of presentation
to our institution shows multiple erythematous papules coalescing
into plaques (A). The skin lesions significantly improved after 8
days of treatment with topical steroids under occlusion and PUVA
phototherapy (B).
a span of 5 years to involve 80% of her body
surface area (Fig. 1A). The patient reported that
her skin rash began as itchy red bumps that she
interpreted as poison ivy. Her lesions progressed
and she eventually sought medical attention. Upon
presentation to an outside dermatologist, she was
noted to have fine erythematous papules and plaques
extensively involving her chest, arms, back and upper
thighs in a background of extreme xerosis. Her
lesions waxed and waned and were variably treated
with courses of topical and oral steroids. Given the
extent of her lesions, she was hospitalized on two
occasions. A biopsy was eventually performed by
her outside dermatologist on a right supraclavicular
plaque. The clinical differential diagnosis included a
drug eruption, atopic dermatitis, urticaria, bullous
pemphigoid and dermatitis herpetiformis. H&E-
stained sections revealed features highly concerning
for MF; however, a lymphomatoid drug reaction
could not be entirely excluded. The patient was
referred to our institution for further evaluation.
At our institution, physical examination revealed
erythematous, scaly, papules and plaques without
vesiculation on the patient’s face, trunk and
extremities with involvement of 80% of her body
surface area. The lesions were not follicularly-based
or annular, and there was no associated alopecia
or ulceration. The clinical differential diagnosis at
this time included MF, eczema and a drug eruption.
Although she was taking several medications, there
was no temporal relationship between the onset of
the patient’s lesions and her medications. Repeat
biopsy from the skin of the left upper arm
demonstrated findings consistent with the diagnosis
of MF. The patient also had palpable right inguinal
lymphadenopathy that was evaluated by positron
emission tomography-computed tomography (PET-
CT) and found to have normal metabolic uptake.
No peripheral blood involvement was identified.
Given her erythrodermic presentation and her skin
biopsy findings, she was diagnosed with MF, stage
IIIA.16 She was treated with inpatient modified
Goeckerman therapy using topical corticosteroids
under occlusion with psoralen plus ultraviolet A
(PUVA) phototherapy. The patient significantly
improved after 8 days of treatment (Fig. 1B). An
ensuing flare of her disease was treated successfully
with 8 days of modified Goeckerman therapy. She
was subsequently lost to follow-up at our institution.
However, review of outside medical records revealed
that the patient ultimately progressed to tumor stage
MF with large cell transformation and expired due to
‘immunodeficiency’. She had two additional outside
biopsies. A biopsy from a right arm plaque revealed
MF with folliculotropism. A subsequent biopsy taken
from a right neck tumor revealed MF with large cell
transformation.
Patient 2
A 67-year-old woman with a long-standing history
of MF, stage IIB with large cell transformation,
presented with an enlarging, erythematous-to-
violaceous nodular plaque on her right shin. This
plaque developed during treatment with bexarotene
(75mg, three times per week), narrow band
ultraviolet B phototherapy three times per week, and
clobetasol. The patient was diagnosed with MF in
2008 and developed tumors with large cell transfor-
mation in 2010. Her diagnosis of MF was confirmed
on multiple biopsies from different anatomic sites,
and included an abnormal immunophenotype and
a monoclonal T-cell population.
Materials and methods
Hematoxylin and eosin-stained sections from the
formalin-fixed, paraffin-embedded tissues were
prepared using a standard protocol. All staining
was performed using a Ventana Benchmark Ultra
automated immunostainer (Ventana Medical
Systems, Tucson, AZ, USA) according to standard
protocols at the University of Michigan Department
of Pathology. The following antibodies were used:
CD2 (Leica Microsystems, Buffalo Grove, IL, USA,
1 : 40), CD3 (Ventana, predilute), CD4 (Leica, 1 :
40), CD5 (Ventana, predilute), CD7 (Ventana,
predilute), CD8 (Ventana, predilute), CD30 (Dako
North America, Inc., Carpinteria, CA, USA, 1 :
100), CD20 (Ventana, predilute), CD79a (Dako,
1 : 100), CD19 (Cell Marque Corporation, Rocklin,
CA, USA, 1 : 25), PAX5 (BD Biosciences, San
Jose, CA, USA, 1 : 25), BCL6 (Ventana, predilute),
and CD10 (Ventana, predilute), and CD3/CD20
dual immunohistochemical study (Ventana, predi-
lute). The chromogen used was 0.05% DAB
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Fig. 2. Hematoxylin and eosin-stained section of a punch biopsy from the left upper arm (Patient 1) demonstrates atypical dermal and
epidermotropic lymphocytes with the formation of Pautrier collections (A,B). A subsequent biopsy also revealed folliculotropism (C). 200× (A),
400× (B) and 100× (C).
(diaminobenzidine tetrahydrochloride, Dako) for
single antigen studies and DAB was combined with
alkaline phosphatase (ultraView Universal Alkaline
Phosphatase Red Detection Kit, Ventana, predilute)
for the CD3/CD20 combined study. DAB was
used for CD20 and alkaline phosphatase red was
used for CD3. The counterstain was Harris hema-
toxylin. All immunohistochemical studies included
appropriately positive and negative controls.
For detection of monoclonal T-cell receptor
gamma chain (TCR-γ) and immunoglobulin heavy
chain (IgH) rearrangement, genomic DNA was
extracted from paraffin-embedded tissue and
amplified by multiplex polymerase chain reaction
using a set of 5′-fluorescent end-labeled primers that
anneal to conserved sequences in the V regions and
J regions of the TCR gene or to the three conserved
framework regions of the IgH gene (FR1, FR2,
FR3). The amplified products were then subjected
to fractionation using capillary electrophoresis and
detected through differential fluorescence emission.
Results
Case 1
Of the patient’s four biopsies, two revealed neoplastic
T-cells with aberrant CD20 expression: a punch
biopsy of a plaque from the left upper arm and
a biopsy of a tumor from the right neck. The
punch biopsy from the left upper arm demonstrated
characteristic features of MF including small-
to medium-sized atypical lymphocytes within the
epidermis and upper dermis that were associatedwith
minimal spongiosis, formed Pautrier collections, and
tagged the dermal-epidermal junction (Figs. 2A,B
and 4A). The lymphocytes were enlarged and
displayed hyperchromatic nuclei and irregular
nuclear contours. In the superficial dermis, they
showed a patchy, band-like distribution and were
associated with wiry fibrosis. Folliculotropism was
not identified in this biopsy; however, a subsequent
biopsy from the right arm revealed follicular
involvement (Fig. 2C). In addition, the T-cell
immunophenotype was abnormal. Specifically, the
epidermotropic lymphocytes in the left arm biopsy
expressed the T-cell markers CD3 (Figs. 3B and
4B,D), CD4 (Fig. 3C) and CD5 (Fig. 3D), but lacked
expression of CD7 (Fig. 3E) and partially lacked
CD2 (expressed by approximately 75% of cells;
Fig. 3A). TheCD4 toCD8 ratiowas greatly increased
(>10 : 1; Figs. 3C,F). A small subset (10–15%) of
atypical dermal and epidermotropic lymphocytes
also expressed CD30. Interestingly, CD20, a B-
cell marker, was expressed in a significant subset
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Fig. 3. Immunohistochemical studies performed on case 1 demonstrate CD2+/− (A), CD3+ (B), CD4+ (C) and CD5+ (D) T-lymphocytes.
The lymphocytes lack expression of CD7 (E) and CD8 (F). The CD4 :CD8 ratio is greatly increased (C, F). The atypical lymphocytes express
CD20 (G), but not CD79a (H). 200× (A–H).
of dermal and epidermotropic atypical T-cells (30%;
Figs. 3G and 4C,D). This finding was confirmed on a
repeat CD20 immunohistochemical study, as well as
a dual CD3 and CD20 immunohistochemical study
(Fig. 4D). These CD20-positive atypical lymphocytes
also appeared to express the T-cell markers CD2,
CD3, CD4 and CD5 (Fig. 3A–D), but did not
express the B-cell markers CD79a (Fig. 3H), CD19,
or PAX5. In addition, no expression of BCL6 or
CD10 was identified.
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Fig. 4. A higher power view (Patient 1) shows epidermotropic lymphocytes (A), with expression of CD3 (B, D) and CD20 (C, D). Co-expression
of CD3 and CD20 is confirmed on a dual CD3/CD20 immunohistochemical study (D; CD3 in red, CD20 in brown). 400× (A–C), 600× (D).
Gene rearrangement studies for TCR-γ and
IgH genes were performed on the left upper arm
biopsy using DNA extracted from paraffin sections.
In addition, gene rearrangement studies were
performed on the patient’s initial right supraclavic-
ular biopsy. Importantly, an identical, monoclonal
rearrangement of the TCR-γ gene was identified in
both the left upper arm and the right supraclavicular
biopsies. There was no clonal rearrangement of the
IgH gene (Table 1).
The right neck tumor revealed sheets of large,
atypical lymphoid cells with nuclear hyperchromasia
and pleomorphism and variably prominent nucleoli
(Fig. 5A). These cells diffusely expressed CD3
(Fig. 5B,E), CD4, CD5 and CD30 (Fig. 5C). They
also showed diffuse, weak expression of CD20 (100%
of cells; Fig. 5D,E), including on a combined CD3
and CD20 immunohistochemical study (Fig. 5E).
They did not express CD79a.
Case 2
Punch biopsy from the right shin revealed a diffuse
dermal infiltrate of mostly large lymphoid cells with
open chromatin and conspicuous nucleoli (Fig. 6A).
These lymphoid cells infiltrated the epidermis,
where they formed small aggregates compatible with
Pautrier collections (Fig. 6B). By immunohistochem-
istry, the large lymphoid cells were CD3-positive
(Fig. 7A,D) and also diffusely, weakly expressed
CD20 (100% of cells; Fig. 7B,D). CD79a (Fig. 7C),
CD19 and PAX5 were negative. CD30 marked a
rare cell. Immunophenotypic evaluation in previous
biopsies in this patient revealed that her lymphoma
was composed of CD4-positive T-cells with loss of
CD2 and CD7 (expressed by <10% of T-cells, each)
and weak, diffuse expression of CD5. Further, a prior
gene rearrangement study showed a monoclonal
T-cell population.
Discussion
Expression of the B-cell marker CD20 is extremely
rare in T-cell neoplasms. Of these neoplasms, CD20
is most commonly identified in peripheral T-cell
lymphomas.6 Here, we report two cases of CD20-
positive MF. In case 1, the patient demonstrated
a more eczematous presentation with papules and
plaques covering more than 80% of her body
surface. A drug reaction was initially considered in
the clinical and histopathologic differential diagnosis,
highlighting that MF is a ‘great imitator’ and may
mimic a variety of clinical entities.17 Given the
patient’s persistent, progressive papules and plaques
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Table 1. Summary of current and reported cases of CD20-positive mycosis fungoides*
Case Reference Age/Sex
T-cell
immunophenotype
B-cell
immunophenotype Molecular studies Clinical course
1 Current 84/F CD2+/−, CD3+,
CD4+, CD5+,
CD7−, CD8−,
CD30+
CD20+ (weak),
CD79a−, CD19−,
PAX5−
TCR-γ clone IgH
negative
Erythroderma treated with topical
steroids under occlusion and PUVA
on two occasions, eventual
development of tumors with large
cell transformation. Dead 2 years
after diagnosis.
2 Current 67/F CD3+, CD4+, CD2−,
CD5+ (weak), CD7−,
CD30−
CD20+ (weak),
CD79a−, CD19−,
PAX5−
TCR-γ clone Progression from patches and plaques
to tumors with large cell
transformation.
3 Martin3 83/M CD2+, CD3+, CD4+,
CD5+, CD7-,
CD30+/−
CD20+, CD79a−,
PAX5−
TCR-γ and TCR-β
clones IgH
negative
Patches and thick plaques with
ulceration. Remission with topical
steroids, radiotherapy, PUVA.
4 Rahemtullah6 74/M CD3+, CD4+, CD5+,
CD7+(weak), CD8−,
CD30+
CD20+, PAX5− TCRγ clone IgH
did not amplify
Multiple skin lesions not further
described. Large cell transformation;
multiple cutaneous relapses. Dead at
35months
5 Rahemtullah6 80/M CD3+, CD4+, CD5+,
CD7−, CD8−,
CD30−
CD20+, CD79a−,
PAX5−
TCRγ clone IgH
negative
Two plaques present for 15-years.
Recent diagnosis at time of
publication.
6 Sen7 53/M CD2+, CD3+, CD4+,
CD5+, CD8−,
CD7−
CD20−/+(weak),
CD79a−, PAX5−
TCR-γ clone IgH
negative
Worsening patches and plaques.
Disease progression to involve
lymph node and form a tumor.
Stable disease after treatment with
bexarotene, PUVA, interferon, and
radiation.
7 Song12 78/M CD3+, CD4−, CD5−,
CD7−, CD8−
CD20+ Unknown Progression from patches and plaques
to tumors with increased large cells
(<25%).
8 Hagen15 14/M CD3+, CD4+, CD5+,
CD7−/+, CD8−,
CD30−
CD20+, CD79a−,
PAX5−
TCR-γ clone Solitary, 3 cm patch. Partial resolution
with topical steroids.
9 Hagen15 44/M CD3+, CD4+,
CD7−/+, CD8−
CD20+/−, PAX5−/+ No TCR-γ clone Patches and plaques with a waxing and
waning course.
10 Hagen15 80/F BF1+, CD2+, CD3+,
CD4+, CD5−/+,
CD7−/+, CD8−
CD20+ TCR-γ clone IgH
negative
Crusted nodules representing
folliculotropic MF with development
of tumors and large cell
transformation.
11 Jullie13 79/M CD3+, CD30−/+ CD20+/−, CD22−,
PAX5−
TCR-γ clone IgH
not amplified
Patches and tumors with large cell
transformation and lymph node
involvement. Eventual death from
disease.
12 Jullie13 32/F CD3+, CD30−/+ CD20+, CD22−,
PAX5−
TCR-γ clone IgH
negative
Patches and tumors with large cell
transformation and lymph node
involvement. Disease progression.
13 Jullie13 50/F CD3+, CD30−/+ CD20+/−, CD22−,
PAX5−
TCR-γ clone IgH
minor clone
Patches and tumors with large cell
transformation and disease
progression.
14 Jullie13 67/F CD3+, CD30− CD20+, CD22−,
PAX5−
TCR-γ clone IgH
not amplified
Patches and tumors with large cell
transformation. Eventual death from
disease.
15 Jullie13 88/F CD3+, CD30−/+ CD20+, CD22−,
PAX5−
TCR-γ clone IgH
not done
Not available
16 Jullie13 92/M CD3+, CD30− CD20+, CD22−,
PAX5−
TCR-γ clone IgH
not amplified
Not available
*+/− Indicates partial expression of antigen with ≥30% of cells positive; −/+ indicates <30% of cells are positive.
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Fig. 5. A subsequent biopsy of a tumor (Patient 1) reveals sheets of large, atypical lymphoid cells (A) that express CD3 (B, E), CD30 (C) and
CD20 (D, E). Co-expression of CD3 and CD20 is confirmed on a dual CD3/CD20 immunohistochemical study (E; CD3 in red, CD20 in
brown). 400X (A–E).
A B
Fig. 6. A punch biopsy (Patient 2) reveals a diffuse dermal infiltrate of large, atypical lymphoid cells (A) that involve the epidermis and form
Pautrier collections (B). 400× (A) and 200× (B).
culminating in tumors and large cell transforma-
tion, along with the classic histopathologic and
immunophenotypic findings and an identical mon-
oclonal T-cell population in distinct anatomic sites,
a diagnosis of MF was made. In case 2, the patient
had a well-established clinical and pathologic history
of MF with tumors and large cell transformation.
To our knowledge, only a handful of CD20-
positive MF cases have been previously reported
(Table 1). Benner et al. noted four of such cases in
a study of prognostic factors in transformed MF.14
However, detailed clinical, immunophenotypic and
genetic information was not provided in this study,
and these cases have not been included in the table
or summarized below. The remaining patients were
described as part of case series,6,15 case reports,3,7,12
and a recent study examining CD20 expression in
transformedMF.13 Incorporating the cases presented
here, patients with CD20-positive MF include nine
males and seven females with an age range of
14–92 years old (Table 1). All cases were positive for
CD20, but lacked expression of other B-cell markers,
such as PAX5, CD79a, CD19 and/or CD22, where
evaluated. In addition, a monoclonal rearrangement
of the TCR-γ gene was identified in 14 of 16 cases.
Case 1 also adds to the few reported cases of papu-
lar MF,18 although this patient also demonstrated
more conventional lesions with large, thin plaques.
500
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Fig. 7. Atypical lymphoid cells (Patient 2) express CD3 (A, D) and CD20 (B, D), but they do not express CD79a (C). Co-expression of CD3
and CD20 is confirmed on a combined CD3/CD20 immunohistochemical study (D; CD3 in red, CD20 in brown), 400× (A–D).
Notably, all of the reported cases of CD20-positve
MF with available clinical information described
more conventional lesions (Table 1): patches and
ulcerated, thick plaques,3 two stable plaques,6 a
solitary 3 cm plaque that partially resolved,15 patches
and plaques with a waxing and waning course,15
crusted nodules representing folliculotropic MF with
progression to tumors,15 and patches and/or plaques
that evolved into tumors.7,12,13 One patient was
reported to have multiple skin lesions, but further
information about the appearance of these lesions
was not provided.6 For two patients, information
regarding the clinical appearance of the lesions was
not provided.13
The clinical course of disease varied amongst cases
of CD20-positive MF (Table 1). However, there
was a trend toward tumor formation and large cell
transformation, even after exclusion of studies that
specifically focused on transformed MF.13,14 Of the
ten patients described in case reports and series
that did not focus on transformed MF, six had
tumors and/or large cell transformation with five
patients developing tumors and four progressing to
large cell transformation.6,7,12,15 Of 13 patients with
available clinical information, five patients remained
stable or improved. Two patients achieved remission
after treatment with topical steroids, PUVA and
radiation,3,7 and one had stable plaques for
15 years.6 Another patient with a solitary 3 cm patch
experienced partial resolution with topical steroids,15
while a fifth with patches and plaques followed
a waxing and waning course.15 The remaining
11 patients experienced disease progression.6,12,13,15
Three patients developed nodal disease,7,13 and
four patients expired of their disease.6,13 Given the
limited number of reported cases and follow-up, it
is unclear whether CD20 positivity has prognostic
significance in MF. Notably, in two large studies on
transformed MF, approximately 4% of patients with
large cell transformation showed aberrant expression
of CD20.13,14
The expression of CD20 in an atypical epider-
motropic infiltrate might lead to consideration of the
diagnosis of B-cell lymphoma, because epidermal
lymphocytes have been reported in rare cases of
B-cell lymphoma.19–24 These reported cases of B-cell
lymphoma with atypical epidermal lymphocytes
were evaluated with at least immunohistochemical
studies for B- and T-cell markers, and some were
also examined for monoclonal B- and T-cell receptor
gene rearrangements. Similarly, nearly all cases
of CD20-positive MF reported thus far have been
distinguished from B-cell lymphomas due to the
lack of other B-cell markers, the presence of T-cell
markers such as CD3 and CD4, and the absence of
a monoclonal IgH gene rearrangement. Further, in
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some cases, co-expression of CD3 and CD20 was
confirmed on a dual immunohistochemical study15
or a dual immunofluorescence study.13 Finally,
in one reported case of CD20-positive MF, flow
cytometry was performed on an involved lymph
node and revealed a population of T-cells that were
positive for CD2, CD3, CD4 and CD5, negative
for CD7, and that also expressed CD20.7 While
epidermal involvement by reactive B-cells has also
been described,25 the absence of other B-cell markers
in virtually all of the reported cases of CD20-positive
MF diminishes the likelihood of a non-neoplastic
B-cell population. A full immunophenotypic and
genetic evaluation in cases of T-cell lymphoma
with aberrant co-expression of CD20 is required to
prevent misdiagnosis and inappropriate treatment.
In the cases presented here, the possibility
of a CD20-positive reactive or neoplastic B-cell
population was considered. However, the similar
distribution of the CD20-positive cells and neoplastic
T-cells in the epidermis and superficial dermis, the
absence of other B-cell markers, and the absence of
a monoclonal B-cell receptor gene rearrangement in
case 1 helped to exclude a B-cell infiltrate. In case
2, the patient had a well-established history of MF
with tumors and large cell transformation, and prior
studies had demonstrated an immunophenotypically
aberrant, monoclonal T-cell population. Notably,
the neoplastic T-cells in the left upper arm biopsy in
case 1 showed only partial expression ofCD20.While
most of the other reported cases of CD20-positiveMF
displayed uniform expression ofCD20, limitedCD20
expression by only a subset of neoplastic T-cells has
also been described.6,13,15
The functionality of CD20 in MF and other T-
cell lymphomas is unclear. Two theories have been
discussed in the literature. First, CD20-positive T-cell
lymphomas may expand from a normal population
of T-cells that are dimly CD20-positive.6,26 Second,
it has been postulated that CD20 may represent
a marker of activation.6 In support of the latter
hypothesis, CD20 expression can be induced in T-
cells in monkey lymph nodes after stimulation by
mitogen, IL-2 and simian immunodeficiency virus.27
In addition, in three cases of CD20-positive MF,
CD20 expression appeared over time and correlated
with disease progression. In one case, sequential
skin biopsies showed a progressive increase in the
proportion of neoplastic T-cells coexpressing CD20
and CD30, eventuating in large cell transformation
(Table 1, case 4).6 In a second case, CD20 was
expressed by T-cells from a subsequent tumor stage
lesion and an involved lymph node, but not from an
initial patch/plaque stage lesion (Table 1, case 6).7
Finally, one of the cases described in this report
showed an increasing percentage of CD20-positive
andCD30-positive T-cells over time and with disease
progression (Table 1, case 1). The role of CD20
in calcium regulation and cellular activation in B-
cells lends support to the hypothesis that CD20 is
a marker of cellular activation. Moreover, 7 of 16
reported cases of CD20-positive MF also showed
co-expression of CD30, the latter a known marker
of T- and B-cell activation28 that may represent an
adverse prognostic indicator in MF.29 Regardless
of functionality, CD20 may be a useful antigen
for therapy. Anti-CD20 antibody therapy has been
used successfully for B-cell lymphomas.2 In cases of
CD20-positive MF refractory to standard therapy,
anti-CD20 therapy could also be considered.6,7,30
In summary, we report two rare cases of
CD20-positive MF. The exact incidence of CD20-
positivity in MF is unknown due to variability in
the immunophenotypic characterization of MF. In
addition, it is unclear whether CD20-positivity may
be influenced by the course of disease or medical
treatment. To fully understand the clinical and
prognostic value of CD20-positivity, more cases
and clinical outcomes need to be identified and
reported.
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